PURE Bioscience Announces an International Supply and License Agreement with AgroVet Alliance
PURE Bioscience has signed a multi-year international supply and license agreement with AgroVet Alliance. This partnership will see the distribution of PURE's patented, non-toxic silver dihydrogen citrate (SDC) antimicrobial products across the Middle East and North Africa. Jeff Kitchell, VP of Operations at PURE, highlighted the strategic fit between PURE's vision and AVA's established network in the animal health sector. AVA's CEO, Nick Nikooforsat, expressed excitement about offering SDC products to their network, emphasizing the potential business impact for their customers. SDC stands out due to its dual-action mechanism, effectively killing a broad spectrum of microbes and having a long shelf life, unlike traditional silver-based disinfectants.
- PURE Bioscience has entered into a multi-year international agreement, expanding its market reach.
- The partnership taps into AVA's established distribution network in the Middle East and North Africa.
- SDC products are positioned as superior to traditional silver-based disinfectants due to their long shelf life and dual-action mechanism.
- AVA’s excitement highlights the positive reception and potential for success in the market.
- The press release does not specify any immediate financial gains or projected revenue increases from the agreement.
- Dependence on AVA’s network could pose a risk if their distribution capabilities falter.
Jeff Kitchell, VP of Operations for PURE, said, “AVA has been doing business worldwide in the animal health and livestock industry for decades. We are excited about AVA’s opportunity to add the SDC family of products to an existing network of distributors and customers in the
Nick Nikooforsat, Chief Executive Officer for AVA, said, “We are extremely excited to add PURE’s SDC products to our network of distributors and partners. This is an opportunity to help our customers make a real difference in the success of their business with SDC.”
How SDC Works
SDC kills microorganisms by two modes of action: 1) the silver ion deactivates structural and metabolic membrane proteins leading to microbial death; 2) the microbes view SDC as a food source, allowing the silver ion to enter the microbe. Once inside the organism, the silver ion denatures the DNA, which halts the microbe’s ability to replicate and leads to its death. This dual action makes SDC highly and quickly effective against a broad spectrum of microbes. Traditional silver-based disinfectants have short shelf lives – from hours to days. SDC is a stabilized silver ion complex with a shelf life of several years. The unique bond between the silver ions in SDC allows the silver ion to remain in solution while at the same time making it more bio-available for antimicrobial action.
About AgroVet Alliance
AVA has served the
About PURE Bioscience, Inc.
PURE focuses on developing and commercializing our proprietary antimicrobial products primarily in food safety. We provide solutions to combat the health and environmental challenges of pathogens and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This is a broad-spectrum, non-toxic antimicrobial agent, and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, and mitigation of bacterial resistance. PURE’s mailing address of 771 Jamacha Rd. #512,
Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release, including quotes from management, concerning the Company’s expectations, plans, business outlook, future performance, future potential revenues, expected results of the Company’s marketing efforts, the execution of contracts under negotiation, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2023, Form 10-Q for the fiscal first quarter ended October 31, 2023, Form 10-Q for the fiscal second quarter ended January 31, 2024, and Form 10-Q for the fiscal third quarter ended April 30, 2024. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618592188/en/
Mark Elliott, VP Finance
PURE Bioscience, Inc.
Phone: 619-596-8600 ext.: 116
Source: PURE Bioscience, Inc.
FAQ
What is the recent agreement between PURE Bioscience and AgroVet Alliance?
What is the significance of the PURE Bioscience and AgroVet Alliance deal?
How does SDC antimicrobial work?
Why is SDC considered superior to traditional silver-based disinfectants?
What regions will benefit from the PURE and AgroVet Alliance agreement?